Carprieve Flavour Tablets for dogs-Hyperdrug

Dosage & Administration For oral administration to dogs. The tablets are palatable and willingly consumed by most dogs when offered. An initial dose of 2 to 4 mg carprofen/kg bodyweight/day is recommended to be given as a single daily dose or in two equally divided doses. The dose may be reduced to 2 mg carprofen/kg bodyweight/day administered as a single daily dose after 7 days, subject to clinical response. Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision. To extend analgesic cover post-operatively, parenteral administration of carprofen, may be followed with Carprieve Tablets at 4mg/ kg/ daily for up to 5 days.

Do not use in cats. The elimination time of NSAIDs, including carprofen, in the cat is longer than in the dog and the therapeutic index is narrower. In the absence of specific data use in the cat is contra- indicated. Do not exceed the stated dose. Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. As with other NSAIDs there is a risk of rare idiosyncratic renal or hepatic adverse effects. Typical undesirable effects associated with NSAIDs, such as vomiting, soft faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions generally occur within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. Do not use in puppies less than 4 months. Use in aged dogs may involve additional risk. If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential rise of increased renal toxicity. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated. Do not use in case of hypersensitivity to active substance or to any of the excipients. Carprofen is highly bound to plasma proteins and compete with other highly bound drugs, which can increase their respective toxic effects. Do not use this veterinary medicinal product concurrently with or within 24 hours of other NSAIDs or concurrently with glucocorticoids. Concurrent administration of potentially nephrotoxic drugs should be avoided. Do not administer concurrently with anticoagulants. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches. For breeding animals, do not use during reproduction period. Due to the palatable nature of the tablets, store in a secure location. Severe adverse reactions may occur if large quantities are ingested. If you suspect your dog has consumed Carprieve Flavoured Tablets above the labelled dose, please contact your veterinarian. In case of accidental ingestion seek medical advice and show the package leaflet or the label to the physician. Wash hands after handling product. Pharmaceutical Precautions Do not store above 25ºC. Store in a dry place. Protect from light Keep out of reach and sight of children. Divided tablets should be stored in the blister pack. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Further Information Carprofen is a member of the 2 –arylpropionic acid group of non steroidal anti-inflammatory drugs (NSAIDs) and possesses anti-inflammatory, analgesic and antipyretic activity. Carprofen like most other NSAIDs is an inhibitor of the enzyme cyclo-oxygenase of the arachidonic acid cascade. However the inhibition of prostaglandin synthesis by carprofen is slight in relation to its anti-inflammatory and analgesic potency. At therapeutic doses in the dog inhibition of the products of cyclo-oxygenase (prostaglandins and thromboxanes) or lipoxygenase (leukotrienes) has been absent or slight. The precise mode of action of carprofen is not clear. After a single oral administration of 4 mg of carprofen per kg of bodyweight in dogs, the time to obtain a maximum plasmatic concentration of 31 g/ml is 2.5 hours. The oral bioavailability is more than 90% of the total dose. Carprofen is more than 98% bound to plasma proteins and its volume of distribution is low. Carprofen is excreted in the bile with 70% of an intra-venous dose of carprofen being eliminated in the faeces, mainly as the glucuronide conjugate. Carprofen undergoes an enantioselective enterohepatic cycle in dogs, with only the S(+) enantiomer being significantly recycled. The plasmatic clearance of the S(+) carprofen is about twice that of the R(-) carprofen. The biliary clearance of S(+) carprofen seems to be subject to stereoselectively too as it is about three times higher than that of R(-) carprofen. Carprofen is mainly excreted in the bile with 70% of an intra-venous dose of carprofen being eliminated in the faeces, mainly as the glucuronide conjugate, and 8-15% via urine.